PROTAC-Mediated NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy

Researchers established NR4A1 as a valid target for cancer immunotherapy and describeed a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1.